Universal Health Services (UHS)
(Delayed Data from NYSE)
$224.66 USD
-4.35 (-1.90%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $224.60 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$224.66 USD
-4.35 (-1.90%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $224.60 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Zacks News
DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.
Zacks.com featured highlights Hilton Grand Vacations, Tenet Healthcare, Universal Health, Popular and B2Gold
by Zacks Equity Research
Hilton Grand Vacations, Tenet Healthcare, Universal Health, Popular and B2Gold have been highlighted in this Screen of The Week article.
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.
Baxter's (BAX) Helion Surgical System Debuts in Thailand
by Zacks Equity Research
Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.
Earnings Estimates Moving Higher for Universal Health Services (UHS): Time to Buy?
by Zacks Equity Research
Universal Health Services (UHS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why Universal Health Services (UHS) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bet on These 5 Top-Ranked Value Stocks With Discounted PEG
by Urmimala Biswas
Invest in some top value stocks such as Hilton Grand Vacations (HGV), Tenet Healthcare (THC), Universal Health Services (UHS), Popular, Inc. (BPOP) and B2Gold Corp (BTG) that fit our screening criteria.
Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines
by Zacks Equity Research
Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline. Operating margin contracts.
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
by Zacks Equity Research
Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.
Universal Health Services (UHS) Is Up 18.18% in One Week: What You Should Know
by Zacks Equity Research
Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
by Zacks Equity Research
Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Fast-paced Mover Universal Health Services (UHS) Is a Great Choice for Value Investors
by Zacks Equity Research
Universal Health Services (UHS) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
by Zacks Equity Research
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
Alphatec's (ATEC) New EOS Insight System to Boost Spine Care
by Zacks Equity Research
Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.
Universal Health (UHS) Q2 Earnings Beat on Acute Care Strength
by Zacks Equity Research
Universal Health's (UHS) second-quarter results benefit from the rising number of patients in the Acute Care Unit. Declining admissions in the Behavioral Health segment partially offset the positives.
Universal Health Services (UHS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Universal Health Services (UHS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Universal Health Services (UHS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 27.89% and 1.52%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
by Zacks Equity Research
AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.
PacBio's (PACB) Revio System to Boost Novogene's German Lab
by Zacks Equity Research
PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
by Zacks Equity Research
HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.